Cigna's Raised 2026 View Looks Underpriced-But Investors Are Still Hesitant

The market focused on the premarket dip, not the guidance upgrade

Cigna's release gave investors two things at once: a solid quarter and a higher 2026 view. Yet the stock initially reacted with a 1% premarket share dip after the company reported total revenues of $71.7 billion, up 7% year over year, and adjusted income from operations of $7.78 per share. That reaction may understate how much the setup improved.

The more important development was the guidance change. Management raised its 2026 outlook for adjusted income from operations to at least $30.45 per share, up $0.10 from its prior projection and slightly above analyst consensus. A beat followed by a full-year upgrade is not the same as a routine sell-the-news quarter.

Cigna's improvement looked broad, not isolated

Full-year 2025 set a strong base

In February, Cigna said 2025 produced $274.9 billion of total revenues and adjusted income from operations of $8.0 billion, or $29.84 per share. Then, in its Q2 2026 update, management pointed to solid operational performance across its diversified portfolio. The growth also looked diversified across segments: Cigna Healthcare adjusted revenues increased 9%, and Evernorth adjusted revenues rose 6%.

That matters because broad-based results are usually more durable than a single-line-item surprise.

Cigna Healthcare showed operating leverage

Cigna Healthcare's results looked stronger operationally, not just enrollments. Adjusted income from operations in the segment rose 17% to $1.3 billion, ahead of the 9% increase in adjusted revenues. Management tied that performance to improved margins in the U.S. Employer business.

The segment also reported higher care utilization, including more behavioral care contacts than in the prior quarter. That can be interpreted two ways: as a utilization risk or as evidence that members are moving into managed-care services the company can coordinate. For now, the cleaner read is that demand is being captured within Cigna's platform rather than flowing to more expensive care settings later.

Evernorth is still growing even as it invests

Evernorth added to the mixed-but-healthier picture. Adjusted revenues climbed 6% to $61.5 billion, even as adjusted income from operations declined 2% to $1.7 billion. Management said the profitability softness reflected client-focused initiatives and large contract renewals.

That is different from a structural break. When revenue still grows while margins temporarily soften, the usual question is whether those investments will start supporting better spread performance later. If that happens, Evernorth may not need another round of member growth to contribute more to earnings.

Why the valuation debate hinges on estimate revisions

The earnings base is firmer than the stock price implies

The near-term case is straightforward. Cigna reported adjusted income from operations of $8.0 billion, or $29.84 per share for full-year 2025, then raised its 2026 view to at least $30.45 per share. That is not a dramatic multiple re-rating story yet, but it does weaken the easy bear case.

Whether the stock looks cheap depends on what happens next to earnings estimates. If analysts keep lifting those numbers, today's valuation may start to look behind the curve rather than fairly set.

What would strengthen the case from here

The next leg higher likely requires a clean handoff from guidance raise to valuation reset. The main signals to watch are:

• whether improved margins in the U.S. Employer business remain the core engine,
• whether higher care contacts improve integration without pressuring margins, and
• whether Evernorth's client-focused initiatives and contract renewals begin to show up in profitability.

If those signals hold, investor hesitation may prove to be a temporary pricing error rather than a durable view of the business.